Keeler is a global manufacturer of ophthalmic instruments and industry pioneer specializing in diagnostic and magnification products. Keeler’s mission is to help bring an end to preventable vision loss, delivering life-changing products and solutions to make a difference.
Jorvec Corp.
Advanced Electrophysiology and Multi-sensory Systems for Human and Rodent Models Stop by Jorvec’s booth and see our advanced visual evoked potential VEP systems and our innovative pattern electroretinogram PERG system with its unique display tablets for high rate visual stimulation and our integrated animal holder. Learn how our technologies can facilitate earlier detection and monitoring of glaucoma, LHON, TBI and other optic neuropathies. We also offer hybrid, multi-sensory systems capable of recording auditory evoked responses (ABR, AEP, OAE, VEMP), other sensory modalities (somatosensory) and event related potentials (P300), in addition to the standard visual modalities all within one device! Allow us to configure a single device capable of broad cognitive assessment. We look forward to the opportunity to discuss how our instruments and services can meet your specific animal and human research needs.
Imagine Eyes
Imagine Eyes is the pioneering leader in cellular-resolution retinal imaging and biomarkers. The company’s devices address unmet needs for advancing clinical research and trials: precise retinal phenotyping to stratify patients for personalized therapy, and sensitive biomarkers to measure natural disease progression and therapeutic effects in less than 6 months. Imagine Eyes supports Investigators, Sponsors, and CROs in implementing novel outcome measures for natural history studies and clinical trials, especially for IRDs such as RP. The rtx1, an extensively validated device for clinical studies and trials, captures subclinical and clinical alterations at the microscopic scale through quick exams. It quantifies cone cells, RPE cells, and micro-vessel wall structure, and monitors atrophy and lesion expansion with micron precision. The M2OCT, a multimodal imaging device with near-histological 3D resolution, brings AOOCT, AOOCTA, and AOSLO to clinical studies and enables new discoveries.
iCare
Icare USA, Inc., is a trusted partner offering cutting-edge technology to aid in diagnosing and screening ocular diseases. The ease of use and operational reliability are the cornerstones of iCare’s success. The iCare product line consists of medical devices for retinal imaging, fundus perimetry and rebound tonometry. We believe that ophthalmic care should be accessible, effortless and reliable. Our mission is to establish the next level of eye care.
Heidelberg Engineering
Heidelberg Engineering continuously optimizes imaging and healthcare IT technologies to provide ophthalmic diagnostic solutions that empower clinicians to improve patient care. From its inception in 1990, the company has collaborated with scientists, clinicians and industry to develop innovative products that deliver clinically relevant benefits.
Good-Lite Company
Good-Lite has stood as an industry cornerstone for over 90 years, earning its reputation as a leading developer and manufacturer of comprehensive visual acuity testing and screening solutions. Everything about our legacy—built on trust, expertise, and innovation—drives us to continually advance methodologies, technologies, and techniques. At the heart of our mission is the early detection of visual impairments, ensuring the highest standard of care for people at every stage of life.
Gerresheimer
Gerresheimer is an innovative system and solution provider and global partner for the pharma, biotech and cosmetics industries. The company offers a comprehensive portfolio of pharmaceutical packaging, drug delivery systems, medical devices and digital solutions. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. With around 13,600 employees and over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. | Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The company offers a comprehensive portfolio of pharmaceutical containment solutions, drug delivery systems and medical devices as well as solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. With 35 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. With around 12,000 employees, the company generated revenues of around €2bn in 2023. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6). www.gerresheimer.com | Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, cartridges, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma, the Group generated revenues of around EUR 2.4bn in 2024 and currently employs around 13,400 people. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6). https://www.gerresheimer.com/en/home
Genentech, A Member of the Roche Group
For more than 40 years, we’ve been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions. We are headquartered in South San Francisco, California.